共 50 条
- [31] Characteristics of circulating tumor DNA (ctDNA) in patients with ER-positive (ER1), HER2-negative (HER2-) metastatic breast cancer (MBC) on different lines of endocrine treatmentANNALS OF ONCOLOGY, 2019, 30Bos, M. K.Kruger, D. T.Jansen, M. P. H. M.Martens, J. W. M.Boven, E.Sleijfer, S.
- [32] Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case ReportCASE REPORTS IN ONCOLOGY, 2020, 13 (01): : 304 - 308Schlotman, AlyssaStater, AdamSchuler, KyleHeideman, JuddAbramson, Vandana
- [33] Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicineCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 114 : 91 - 101Matikas, AlexiosFoukakis, TheodorosBergh, Jonas
- [34] Axillary Response to Neoadjuvant Therapy in Node-Positive ER-Positive, HER2-Negative Breast CancerANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S236 - S236Friedman-Eldar, OrliOzmen, TolgaReyes, Fernando ValleGoel, NehaTjendra, YouleyKesmodel, Susane B.Moller, MeckerFranceschi, DidoAvisar, Eli
- [36] Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trialANNALS OF ONCOLOGY, 2018, 29 (08) : 1748 - 1754Malorni, L.Curigliano, G.Minisini, A. M.Cinieri, S.Tondini, C. A.D'Hollander, K.Arpino, G.Bernardo, A.Martignetti, A.Criscitiello, C.Puglisi, F.Pestrin, M.Sanna, C.Moretti, E.Risi, E.Biagioni, C.McCartney, A.Boni, L.Buyse, M.Migliaccio, I.Biganzoli, L.Di Leo, A.
- [37] Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancersNPJ BREAST CANCER, 2024, 10 (01)Hilbers, Florentine S.Poncet, CoralieTryfonidis, KonstantinosViale, GiuseppeDelaloge, SuzettePierga, Jean-YvesBrain, Etienne G. C.Rubio, Isabel T.Thompson, Alastair M.Rutgers, Emiel J. T.Piccart, Martine J.van 't Veer, Laura J.Cardoso, Fatima
- [38] The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancerFUTURE ONCOLOGY, 2024, 20 (32) : 2457 - 2466Fjermeros, KamillaGhannoum, SalimGeisler, Stephanie B.Bhargava, SameerTahiri, AndlienaKlajic, JovanaLuders, TorbenFongard, MarieNawaz, Meh SameenBosnjak-Olsen, TatjanaBuvarp, Unn-Cathrin EdvardsenJohanna Rosenskiold, Aino KatriNguyen, Nam ThiSletbak, Tone TyskoSeyedzadeh, ManouchehrSelsas, KnutPorojnicu, Alina CarmenSkjerven, Helle KristineHovda, ToneSahlberg, Kristine KleiviTorland, Lilly AnneLyngra, MarianneHammarstrom, Clara LouiseHonigsperger, Elma BahonjicNoone, John ChristopherMathiassen, SiljeHurtado, AntoniGoel, ShomKoff, AndrewTekpli, XavierKristensen, Vessela N.Geisler, Juergen
- [39] Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast CancerBREAST CARE, 2022, 17 (06) : 561 - 566Jung, WonguenKim, KyuboMoon, Byung-In
- [40] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancerFUTURE ONCOLOGY, 2023, : 727 - 736Kahraman, SedaErul, EnesSeyyar, MustafaGumusay, OzgeBayram, ErtugrulDemirel, Burcin CakanAcar, OmerAksoy, SercanBaytemur, Naziyet KoseSahin, ElifCabuk, DevrimBasaran, GulPaydas, SemraYaren, ArzuGuven, Deniz CanErdogan, Atike PinarDemirci, UmutYasar, AlperBayoglu, Ibrahim VedatHizal, MutluGulbagci, BurcuPaksoy, NailDavarci, Sena EceYilmaz, FundaDogan, OzlemOrhan, Sibel OyucuKayikcioglu, ErkanAytac, AliKeskinkilic, MerveMocan, Eda EylemerUnal, Olcun UmitAydin, EsraYucel, HakanIsik, DenizEren, OnderUluc, Basak OyanOzcelik, MelikeHacibekiroglu, IlhanAydiner, AdnanDemir, HacerOksuzoglu, BernaCilbir, EbruCubukcu, ErdemCetin, BulentOktay, EsinErol, CihanOkutur, Sadi KeremYildirim, NilgunAlkan, AliSelcukbiricik, Fatih